COMPASS Pathways Secures Term Loan Facility for Up to $50
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to...
Source: globenewswire.com
📰 Access Pathway News
Page 8 - Access Pathway News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Access Pathway. Real-time updates on events, politics, business and more.
Global Immunomodulators Devices Market to Grow at a Notable CAGR of 5.19% by 2028, Estimates DelveInsight | Petrovax, Acrotech, Astellas, Merck, Biocon, Zydus, Roche, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Horizon Therapeutics, Sun Pharmaceutical, Teva Pharmaceuticals |
As per DelveInsight, the global Immunomodulators market is estimated to grow at a CAGR of 5.19% during the forecast period from 2023 to 2028. The rising
United Kingdom America Immunomodulators Shruti Thakur Merck Co Inc Provention Bio Inc Immunomodulators Devices Porter Five Forces Analysis
Source: medgadget.com
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 ... | June 12, 2023
United Kingdom Wells Fargo Securities Exchange Commission Avrobio Inc Private Securities Litigation Reform Act Innovative Licensing
Source: marketscreener.com
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
10.06.2023 - Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval ...
Source: wallstreet-online.de
Vertex Pharmaceuticals Incorporated: FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
First CRISPR gene-editing filings to be accepted for review by FDA - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT)
Source: finanznachrichten.de
Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
Source: financialcontent.com
Vertex Pharmaceuticals Incorporated: Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - Data continue to demonstrate transformative and durable benefit - Safety profile consistent with busulfan
Source: finanznachrichten.de
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
- Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent... | June 9, 2023
Source: marketscreener.com
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
Source: prnewswire.com
Biogen Inc.: FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease The
Source: finanznachrichten.de